Human observational studies link higher IL-6 with older age and higher cardiovascular event risk, and associate IL-6 with frailty in people with multiple sclerosis. Human trials report decreases with several exercise and dietary interventions, but an hour of aerobic exercise increases IL-6 in untrained people with type 2 diabetes; a nicotinamide riboside trial shows no clear effect.
1,600 findings in 1,306 papers from 1993 to 2026, 183 of them since April 2026
“Higher IL6 levels were associated with a decreased likelihood of being a "good responder" (OR = 0.22, p = 0.018, 95% CI 0.06; 0.78)”
“Multilevel meta-analysis showed that exercise intervention could significantly reduce the levels of IL-6 (SMD = -0.31), CRP (SMD = -0.44), and TNF-α (SMD = -0.40) in the elderly.”
Exercise decreases IL-6 in older adults with 1 chronic disease.
“Repeated measures ANOVA demonstrated significant decrease in both IL-6 and cortisol for CD1 (p’s <.01) following the intervention, but not for CD0 and CD2.”
Human trialin older adults with 1 chronic disease6 monthsn = 43
Exercise increases IL-6 in humans (moderate exercise).
“Additionally, only female participants exhibited an increase in circulating IL-6 levels post-exercise indicating a sex-specific inflammatory response to moderate exercise.”
“After physical activity, the plasmatic concentration of IL‐6 and the IL‐6/IL‐10 ratio was reduced in frail subjects specifically (p < 0.05), which was paralleled by a slight increase in TNF‐a (p < 0.05).”
↓downin humans9↔no changein humans3↑upin humans1−50% to −21%
13 studies
Resistance training decreases IL-6 in humans.
“The intervention also reduced plasma IL-6 concentrations and markedly increased circulating IL-10 and Klotho levels, indicating a favorable anti-inflammatory and anti-aging response.”
Human trialsupervised programplasmathree sessions/week12 weeksn = 60
“After the 4‐week resistance‐training exposure, the biomarker profile shifted toward lower circulating inflammatory tone and higher peripheral neurotrophic signaling, with interleukin‐6 and tumor necrosis factor‐alpha decreasing while BDNF increased.”
Resistance training decreases IL-6 in humans (-0.74 pg/mL).
“The corresponding mean changes were -0.74 pg/mL for IL-6, -0.49 pg/mL for TNF-α, and +2.7 ng/mL for BDNF, with all paired comparisons statistically significant.”
Resistance training showed no clear effect on IL-6 in humans.
“Between exercise and control group effects and group x cognitive status interaction effects derived from the ANCOVA test were nonsignificant for IGF-1, IL-6, and KYN.”
“After adjustment for baseline values using ANCOVA, significant between-group differences were observed for all circulating biomarkers, consistently favoring the exercise group.”
Aerobic exercise decreases IL-6 in humans (People with overweight or obesity; versus control) (Hedges g 0.70 (95% CI 0.32 to 1.07); positive values indicate greater IL-6 reduction).
“AE versus control was 0.70 (0.32 to 1.07)”
ReviewPeople with overweight or obesity; versus control
↓downin human cells2↔no changein humans2↑upin mice2↓downin rats1
7 studies
Resveratrol decreases IL-6 in rats (spinal cord injury; treatment beginning 14 days post-injury).
“Resveratrol supplementation, alone and combined with exercise, significantly reduced spinal cord IL-6 relative to control, whereas exercise alone did not.”
Resveratrol decreases IL-6 in human cells (Basal conditions and peroxide-induced oxidative environment).
“A decrease in these two cytokines was also observed in cells treated with resveratrol, both at basal levels and in an oxidizing environment (with peroxide).”
CellsBasal conditions and peroxide-induced oxidative environmentleukocyte5μm24 hours
Metformin decreases IL-6 in humans (Peri-implantitis; adjunctive to mechanical debridement versus mechanical debridement alone) (8.13 pg/mL vs. 19.23 pg/mL).
“IL-6 levels (8.13 pg/mL vs. 19.23 pg/mL, P < 0.001) compared with the control.”
Human trialPeri-implantitis; adjunctive to mechanical debridement versus mechanical debridement alonegelperi-implant crevicular fluid1%6 monthsn = 54
Combined aerobic and resistance training decreases IL-6 in humans (pooled across RCTs in postmenopausal women with overweight or obesity) (SMD = -1.58, 95% CrI [-2.62, -0.56]).
European journal of oncology nursing : the official journal of European Oncology Nursing Society·
Combined aerobic and resistance training decreases IL-6 in type 2 diabetes mellitus patients with overweight or obesity (SMD = -0.93, 95% CI: -1.63, -0.23, P = 0.01).
“CE appears to offer the greatest potential in lowering IL-6 (SUCRA=76.6; SMD=-0.93; 95% CI: -1.63, -0.23; P=0.01) levels.”
Reviewin type 2 diabetes mellitus patients with overweight or obesity
“Though these outcomes would not have survived corrections for multiple comparisons, there were significant post-treatment increases in the following multifunctional biofluid proteins: plasma fractalkine and MMP-7, and CSF IL-6; other analytes that displayed trends toward change at P < 0.1 were plasma eotaxin and VEGF ( and Supplementary Table 2”
“CSF levels of interleukin-6 (IL-6) and glial fibrillary acidic protein (GFAP) increased (t(4) = 3.913, P = 0.008 and t(4) = 3.354, P = 0.028, respectively)”
“In CSF, thymus- and activation-regulated chemokine (TARC), IL-17A, I-TAC, eotaxin-2, eotaxin and MIP-1α levels decreased and IL-6 levels increased from baseline to post-treatment.”
SGLT2 inhibitors are linked with lower IL-6 in humans (newly diagnosed T2DM, baseline-adjusted vs metformin monotherapy) (B = -37.87, β = -0.31, 95% CI -73.52 to -2.23).
“treatment group was associated with a lower six-month IL-6 level (B = -37.87, β = -0.31, p = 0.038; 95% CI, -73.52 to -2.23)”
Humansnewly diagnosed T2DM, baseline-adjusted vs metformin monotherapy6 months
SGLT2 inhibitors decrease IL-6 in humans (diabesity).
“Both classes consistently lower levels of systemic cytokines such as IL-6 and hsCRP and improve endothelial function, collectively mitigating cardiometabolic risk.”
Insulin decreases IL-6 in humans (scheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesia) (P = 0.034, P = 0.044).
“inhibited postoperative IL-6 and S100-β levels in Group I compared to Group S (P = 0.034, P = 0.044, respectively)”
Human trialscheduled for elective orthopaedic surgery or pancreatic surgery with general anaesthesiaintranasal administrationserum40 IU/400 μLfrom 5 minutes before anaesthesia induction until 3 days postoperativelyn = 140
“Besides, the serum levels of IL-6, TNF-α and S100β at T2−5 in the insulin group were significantly lower than those of the control group (IL-6: mean difference at T2, −4.14, p = 0.036; T3, −3.84, p = 0.039; T4, −3.37, p = 0.013; T5, −2.57, p = 0.042”
Human trialintranasalserumstarting 2 days before surgery until 1 h before admission to the operating roomn = 61
GLP-1 receptor agonists decrease IL-6 in humans (diabesity).
“Both classes consistently lower levels of systemic cytokines such as IL-6 and hsCRP and improve endothelial function, collectively mitigating cardiometabolic risk.”
GLP-1 receptor agonists showed no clear effect on IL-6 in patients with type 2 diabetes mellitus (SMD = -0.52, 95% CI [-1.34 to 0.29], P = 0.21).
“Although the results from 13 studies indicated a decreasing trend in IL-6 levels (SMD = -0.52), this change was not statistically significant (95% CI [-1.34 to 0.29], P = 0.21”
Reviewin patients with type 2 diabetes mellitusn = 1,878
Nicotinamide riboside showed no clear effect on IL-6 in humans.
“We measured plasma levels of the SASP cytokine IL-6 and found higher levels in patients with COPD compared to lung-healthy controls, but no effects of NR treatment could be detected.”
Journal of the American Medical Directors Association·
Aerobic training showed no clear effect on IL-6 in rats (spinal cord injury; training beginning 14 days post-injury).
“Resveratrol supplementation, alone and combined with exercise, significantly reduced spinal cord IL-6 relative to control, whereas exercise alone did not.”
Animalsspinal cord injury; training beginning 14 days post-injurybody-weight-supported treadmill trainingspinal cord4 weeksmales
Blood flow restriction training increases IL-6 in humans Within-group change; greater increase than non-exercising control (+8.26 pg/mL from baseline).
“IL-6 increased significantly following both BFRT (mean change = 8.26 pg/mL, p < 0.001) and EOE (mean change = 3.56 pg/mL, p = 0.013)”
Human trialWithin-group change; greater increase than non-exercising controlSingle exercise boutmales
“IL-6 emerged as a consistent significant mediator of the relationship between CRF and EF, episodic memory, visuospatial processing and working memory.”
Humansparallel mediation models adjusted for age, sex, APOE4 carriage, body fat percentage, study site and years of education; association of CRF with EF, episodic memory, visuospatial processing and working memoryn = 648
IL-6 is linked with cognitive function in humans (between mushroom intake and Montreal Cognitive Assessment score) (12.76% mediation).
“The association between mushroom intake and MCI was mediated by interleukin-6 (IL-6) and hypersensitive C-reactive protein (hs-CRP), and the MoCA score was 12.76% and 47.59%, respectively.”
Humansbetween mushroom intake and Montreal Cognitive Assessment scoren = 248
IL-6 induces cellular senescence in cells (Intracellular IL-6 signaling).
“This pathway triggered by intracellular IL-6 significantly contributes to cell-autonomous induction of senescence and impacts in tumor growth control.”
IL-6 induces cellular senescence in neighboring uninfected cells.
“HCMV-infected RPTECs have the ability to trigger a senescence/inflammatory loop in an IL-6-dependent manner, leading to the development of a similar senescence/inflammatory phenotype in neighboring uninfected cells”
IL-6 is linked with frailty in humans (ACME 0.052 (95% CI 0.020-0.087, P = .002)).
“association between DII and frailty was significantly mediated by IL-6 (average causal mediation effect [ACME], 0.052; 95% confidence interval, 0.020-0.087; P = .002)”
Humansin patients with colorectal cancer, adjusting for age, sex, BMI, education, smoking, and energyn = 126
The journals of gerontology. Series B, Psychological sciences and social sciences·
Cardiovascular risk reclassification separation
↑upin humans1
1 study
IL-6 is linked with better cardiovascular risk reclassification separation in humans Among reclassified individuals; compared with high-sensitivity C-reactive protein (Event-rate separation 1.15 versus 0.54 per 1,000 person-years).
“Among reclassified individuals, IL-6 separated upward- versus downward-reclassified event rates more than twice as effectively as hsCRP (1.15 vs 0.54 per 1,000 person-years).”
HumansAmong reclassified individuals; compared with high-sensitivity C-reactive protein10 years
IL-6 is linked with cardiovascular disease risk in humans (23.8% mediated by IL-6; 35.7% jointly mediated by IL-6, CRP, and BMI).
“Multi-mediator path analysis attributed 35.7% of the total UPF-CVD association (HR 1.080) to the three joint mediators (IL-6: 23.8%, CRP: 10.4%, BMI: 1.6%).”
Humansmediation of the association between ultra-processed food consumption and cardiovascular disease
Age is linked with higher IL-6 in humans (COVID-19) (p = 0.026).
“Patients aged ≥65 years had significantly higher levels of IL-1β ( p = 0.036), IL-1Ra ( p = 0.025), IL-6 ( p = 0.026), IL-8 ( p = 0.014), IL-10 ( p = 0.005)”
DunedinPoAm38 is linked with IL-6 in humans (Association of food stamp receipt with IL-6; adjusted for sex and self-reported race) (23.2% of total effect mediated; FDR p=0.028).
“with 23.2% of the sex- and race-adjusted total effect mediated by age 15 PoAm38 on 450K (N=355; FDR p=0.028).”
HumansAssociation of food stamp receipt with IL-6; adjusted for sex and self-reported race450Kn = 355
Coronary artery disease is linked with higher IL-6 in humans.
“Across the CAD spectrum, a stepwise increase in systemic IL-6, TNF-α, MCP-1, ICAM-1, and VCAM-1 were observed, reaching peak levels during acute STEMI.”
Humansstepwise rise from healthy subjects through stable CAD to acute STEMI; MCP-1, ICAM-1 and VCAM-1 rose similarly
↑upin humans17↓downin humans2↕mixedin humans1+1% risk of death per unitHR 0.52–3.5
20 studies
IL-6 predicts mortality in humans (IL- 6 level >= 11.2 pg/mL vs < 11.2pg/mL) (adjusted HR 3.5, 95% CI 1.95-6.28, p < 0.001).
“Compared to patients with low IL- 6 level < 11.2pg/mL, patients with high levels had a more than 3-fold increase in mortality at 30-days (adjusted HR 3.5, 95% CI 1.95-6.28, p < 0.001)”
Human trialIL- 6 level >= 11.2 pg/mL vs < 11.2pg/mL30-dayn = 996
IL-6 is linked with a higher risk of mortality in humans (CHF patients with anemia; 4th IL-6 quartile; univariate Cox regression) (1.087 (1.007–1.174)).
“revealed a significant effect of IL-6 on the risk of death from cardiovascular and non-cardiovascular causes in 4QR patients”
HumansCHF patients with anemia; 4th IL-6 quartile; univariate Cox regressionup to 24 months
IL-6 is linked with a higher risk of frailty in humans (chronic obstructive pulmonary disease) (OR 1.454, 95% CI 1.113–2.006).
“serum interleukin-6 (OR = 1.454, 95%CI: 1.113 ~ 2.006) and serum hemoglobin concentration (OR = 0.675, 95%CI: 0.225 ~ 0.901) were the influencing factors of the frailty of older adults with COPD”
Sarcopenia is associated with IL-6 in humans (adjusted for BMI, age, and disease duration) (p < 0.05).
“the cytokines IL-1α, IL-6, and TNFβ concentrations were significantly higher (p < 0.05) in patients with sarcopenia, adjusted for BMI, age, and disease duration.”
Humansadjusted for BMI, age, and disease durationfemalesn = 165
Journal of the American Medical Directors Association·
Sarcopenia is associated with IL-6 in patients with sarcopenia compared to controls.
“Patients with sarcopenia exhibited elevated interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-alpha (TNF-α) levels compared to controls”
Reviewin patients with sarcopenia compared to controls
Sarcopenia is associated with IL-6 in humans with sarcopenia vs without sarcopenia (SMD = 0.31; 95% CI 0.18, 0.44).
“Meta-analysis revealed significantly elevated serum IL-6 levels in older adults with sarcopenia compared with those without sarcopenia (SMD = 0.31; 95% CI 0.18, 0.44).”
Reviewwith sarcopenia vs without sarcopenian = 3,902
IL-6 is associated with cognitive function in humans (r = -0.313).
“Furthermore, there was a significant negative correlation between changes in IL-6 level and changes in memory search score when combining experimental and control group (r = -0.313, p = 0.038) (see Additional file ).”
European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity·
IL-6 is associated with cognitive function in humans.
“Increased levels of IL-6 were also associated with poorer performance in all cognitive domains, but these associations did not survive multiple comparisons correction.”
IL-6 is associated with cognitive function in humans (cross-sectional).
“Higher IL-6 (OR: 1.33; 1.06, 1.66, p = 0.01), TNF-α (OR: 1.35; 1.09, 1.67, p = 0.01) and IL-6:IL-10 Ratio (OR: 1.43; 1.17, 1.74, p = 0.001) were cross-sectionally associated with impaired global RBANS performance.”
IL-6 predicts heart failure in humans (per 1-SD higher log[IL-6] in adults with T2D and overweight/obesity) (HR: 1.43; 95% CI: 1.16-1.75).
“Higher IL-6 was significantly associated with higher risk of incident HF in the overall cohort (HR: 1.43; 95% CI: 1.16-1.75 per 1-SD higher log[IL-6])”
Human trialper 1-SD higher log[IL-6] in adults with T2D and overweight/obesityn = 1,507
IL-6 is associated with heart failure in humans (IL-6 at or above cohort- and sex-specific medians; adjusted for CKM stage) (HR 1.69, 95% CI 1.41–2.03).
“Higher IL-6 and hsCRP were each associated with higher cardiovascular and mortality risks independent of early-stage CKM syndrome.”
HumansIL-6 at or above cohort- and sex-specific medians; adjusted for CKM stagen = 9,894
IL-6 is associated with atherosclerotic cardiovascular disease in humans (IL-6 at or above cohort- and sex-specific medians; adjusted for CKM stage) (HR 1.48, 95% CI 1.33–1.64).
“IL-6 at or above the median was associated with higher risks of atherosclerotic CVD (hazard ratio, 1.48; 95% CI, 1.33–1.64)”
HumansIL-6 at or above cohort- and sex-specific medians; adjusted for CKM stagen = 9,894
IL-6 is linked with a higher risk of atherosclerotic cardiovascular disease in humans after adjusting for LE8 metrics and demographics (HR 1.54 [1.05-2.25], p = 0.03).
“Increased IL-6 was independently associated with ASCVD (HR 1.54 [1.05-2.25], p = 0.03)”
Humansafter adjusting for LE8 metrics and demographics12 yearsn = 1,869
Cognitive impairment is associated with IL-6 in older adults (12% in normal vs 30-55% in impaired).
“12% of cognitively normal older adults had IL-6 levels in the highest tertile, but this increased in cognitively impaired cohorts-36% in Alzheimer's disease, 55% mixed dementia, 30% mild cognitive impairment, and 39% vascular mild cognitive impairment.”
Older age is associated with IL-6 in rats (elder versus young adult Wistar albino rats).
“TNF-α, IL-6, GRP78, and MAPK protein levels were shown to increase significantly in aged rat kidneys, whereas occludin levels decreased significantly.”
Animalselder versus young adult Wistar albino ratskidney
“overweight and obese middle-aged and elderly individuals show elevated levels of inflammatory markers like CXCL-16, IL-6, and adipokines compared to normal weight counterparts.”
Atherogenic Central Load Index is associated with IL-6 in humans (r = −0.48 before, r = −0.59 after).
“Different results were obtained when IL-6 values were correlated with AIP and ACLI values at the two evaluation times, before: IL-6 vs. ACLI, r = −0.48, p < 0.001, B; after: IL-6 vs. ACLI, r = −0.59, p < 0.001, D), compared to the results of the IL-6 vs. AIP correlation (before: IL-6 vs. AIP, r = −0.13”
Dietary inflammatory index is associated with IL-6 in lipedema group.
“A significant positive correlation was also observed between baseline DII and IL-6 levels in the lipedema group, but not in the overweight/obesity group.”
Human studies associate higher IL-6 with mortality and cardiovascular events, link it to cognitive frailty, and report that it predicts immunosenescence. Human trials report decreases with exercise, whole grains, and curcumin, but exercise results also include increases and no change across different populations and protocols.
Summary rewritten as its findings changed.
As it read before
Higher IL-6 is associated with mortality in human cohorts; other human studies link IL-6 to chronological age, frailty and PhenoAge. Exercise training trials report decreases in older adults with chronic disease or people with sarcopenia; a trial reports an increase after a treadmill session in untrained adults with type 2 diabetes.
Summary rewritten as its findings changed.
As it read before
Human cohorts associate IL-6 with mortality, frailty, cardiovascular events and cognitive impairment. Human exercise trials report decreases, but a trial reports an increase after an hour of treadmill walking in untrained people with type 2 diabetes; nicotinamide riboside leaves plasma IL-6 unchanged in stable COPD.
Summary rewritten as its findings changed.
As it read before
Human cohorts associate higher IL-6 with heart failure, cardiovascular events, mortality and frailty. A human exercise trial reduces IL-6 in HFrEF with permanent AF, whereas another increases it in FM patients. SGLT2 inhibitors decrease IL-6 in newly diagnosed type 2 diabetes, whereas a review reports no effect.
Summary rewritten as its findings changed.
As it read before
In human cohorts, IL-6 associates with age, mortality, pre-pregnancy obesity, plasma p-Tau217, and higher heart failure risk. Human trials show that high-intensity interval training or fasting combined with a ketogenic diet decreases IL-6, while aquatic exercise has no effect.
An experiment in male mice found poorer strength-test performance in middle-aged Alzheimer's model mice than controls, despite preserved muscle size and general motor…An experiment in male mice found poorer strength-test performance in middle-aged Alzheimer's model mice than controls, despite preserved muscle size and general motor performance.
Loneliness was linked to higher fracture odds in men, with an odds ratio of 2.46, but not women, in a prospective cohort of 2,850 adults.Loneliness was linked to higher fracture odds in men, with an odds ratio of 2.46, but not women, in a prospective cohort of 2,850 adults.